Early research suggests GLP-1 drugs could prevent or treat Alzheimer's Disease. Results from a big clinical trial could soon ...

SaveHealth provides an overview of Alzheimer's disease, including treatment and coping mechanisms for those with the disease ...

This essay is adapted from his upcoming book, “Doctored: Fraud, Arrogance, and Tragedy in the Quest to Cure ... there’s another, sinister, factor at play. Over the past 25 years, Alzheimer’s ...

Xenon is one of the six noble gases. Its name derives from the Greek word for “strange”. In medicine, it has been used as an ...

Eisai and Biogen announced FDA approval for LEQEMBI’s once every four weeks maintenance dosing for Alzheimer’s disease ... treatment decisions for healthcare providers. There are safety ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Alzheimer's disease, a devastating neurodegenerative condition that impacts millions globally, may have found an unexpected ...

LEQEMBI is indicated for the treatment of Alzheimer's disease (AD) in patients with mild cognitive impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD ...

on the primary endpoint of the Clinical Dementia Rating-Sum of Boxes (CDR-SB) global cognitive and functional scale. Over three years of treatment across the Clarity AD core study and LTE ...

Once every four weeks maintenance dosing may be easier for patients and care partners to continue treatment Alzheimer's disease progression ... although ARIA can occur at any time, and patients ...

LEQEMBI is indicated for the treatment of Alzheimer's disease (AD) in patients with mild cognitive impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD) in the U.S.

In fact, there is another common cognitive disorder with very similar symptoms, called limbic-predominant age-related TDP-43 encephalopathy — or LATE for short — that is often misdiagnosed as ...